<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aminoacylase 1 (ACY1) is a cytosolic enzyme responsible for amino acid deacylation during intracellular protein degradation </plain></SENT>
<SENT sid="1" pm="."><plain>ACY1 has been implicated in a number of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types </plain></SENT>
<SENT sid="2" pm="."><plain>However, the exact role of ACY1 in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development remains elusive because it was found to be lost in <z:e sem="disease" ids="C0149925" disease_type="Neoplastic Process" abbrv="SCLC">small cell lung cancer</z:e> and <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo> but overexpressed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The present study aims to further clarify the relationship of ACY1 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> progression </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemical staining was performed in tissue microarrays composed of 120 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> using a monoclonal anti-ACY1 antibody </plain></SENT>
<SENT sid="5" pm="."><plain>Immunoreactivity was analyzed in association with patients' clinicopathologic parameters and survival time </plain></SENT>
<SENT sid="6" pm="."><plain>The role of ACY1 in cell proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was assessed by silencing its expression in HCT116 cells using a small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Strong expression of ACY1 was found to be significantly associated with more advanced TNM stage, lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, positive vascular invasion, and shorter <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival </plain></SENT>
<SENT sid="8" pm="."><plain>ACY1 knockdown significantly inhibited cell proliferation and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>We concluded that ACY1 expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> varies with stage and appears to play a role in cell proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Further evaluation of ACY1 as a clinically useful prognostic marker and a potential drug target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> would seem worthwhile </plain></SENT>
</text></document>